PathKeeper Surgical Selected to Exhibit at Vizient Innovative Technology Exchange

PathKeeper Surgical has been selected to exhibit their Artificial Intelligence (AI) and Optical Spine Navigation solution at the Vizient Innovative Technology Exchange. Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange Sept. 18 in Las Vegas.

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their product or service to supply chain and clinical leaders from Vizient’s customer hospitals and subject matter experts who serve on their supply councils. Each product or service will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.

PathKeeper Surgical is working to revolutionize Spinal Navigation with AI and IR Laser Optics. These combine to create a digital surgical platform, with no intraoperative radiation and accuracy for registration and tool tracking to less than a millimeter. Furthermore, it enhances surgical workflows, greatly reduces radiation to patients, and delivers a solution that can help across multiple settings including the Ambulatory Surgery Center as well as for Deformity Surgeons in hospitals.

“We are very excited to bring PathKeeper to the Vizient Innovative Technology Exchange,” said Erez Lampert, CEO of PathKeeper. “Our mission is to revolutionize the spine surgical landscape by integrating advanced technologies that prioritize patient safety and surgical precision. Our advancement significantly enhances surgical workflows and reduces radiation exposure, benefiting both patients and medical professionals. We are excited to bring our innovative solution to market with Vizient, where it can make a real difference in diverse surgical settings, democratizing technology for spine surgeons and patients everywhere.”

“The selection process for medical device and supply companies that exhibit at the Exchange is a rigorous one,” said Kelly Flaharty, senior director of contract services, Vizient. “Companies showcase their products and services hoping to be awarded an Innovative Technology contract — a signal to healthcare providers of their solution’s unique qualities.”

The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by provider-led councils. Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version